Keywords: Celgene, Apremilast, Psoriasis, Sanofi, Regeneron, Dupilumab, Atopic dermatitis, AAD meeting

AAD conference briefs: Celgene's apremilast; and Sanofi's dupilumab

Article | 04 March 2013

Print This

The European subsidiary of US biotech firm Celgene Corp (Nasdaq: CELG) presented the results from ESTEEM 1 with its drug candidate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in